OncoMatch/Clinical Trials/NCT07078500

Orelabrutinib Combined With Pola-R-CHP Regimen for the Treatment of Untreated Non-GCB Diffuse Large B-Cell Lymphoma

Is NCT07078500 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies orelabrutinib combined with the Pola-R-CHP regimen for diffuse large b-cell lymphoma (dlbcl).

Phase 2RecruitingSecond Affiliated Hospital, School of Medicine, Zhejiang UniversityNCT07078500Data as of May 2026

Treatment: orelabrutinib combined with the Pola-R-CHP regimen — Assess the preliminary efficacy and safety of orelabrutinib in combination with the Pola-R-CHP regimen for the treatment of treatment-naive Non-GCB diffuse large B-cell lymphoma.

Check if I qualify

Extracted eligibility criteria

Cancer type

Diffuse Large B-Cell Lymphoma

Non-Hodgkin Lymphoma

Performance status

ECOG 0–2(Ambulatory, capable of self-care)

Prior therapy

No prior treatment (treatment-naive required)

Max 0 prior lines

Lab requirements

Blood counts

Neutrophils <1.5×10⁹/L; Platelets <75×10⁹/L [excluded]

Kidney function

Creatinine level more than 1.5 times the upper limit of normal [excluded]

Liver function

ALT or AST more than 2 times the upper limit of normal, ALP and bilirubin more than 1.5 times the upper limit of normal [excluded]

Laboratory values at screening (unless due to lymphoma): Neutrophils <1.5×10⁹/L; Platelets <75×10⁹/L; ALT or AST more than 2 times the upper limit of normal, ALP and bilirubin more than 1.5 times the upper limit of normal; Creatinine level more than 1.5 times the upper limit of normal.

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify